nonalcoholic fatty liver disease
Conditions
Interventions
Lactobacillus rhamnosus CCFM1060 group:Lactobacillus rhamnosus CCFM1060
Bifidobacterium adolescentis CCFM1062 group:Bifidobacterium adolescentis CCFM1062
Placebo group:Placebo
Sponsors
Yixing People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Meet the diagnostic criteria for non-alcoholic fatty liver disease; 2. Aged 18-65 years, no gender limit; 3. Overweight or obese (2590 cm (male), >85 cm (female)); 4. Good compliance, able to comply with the requirements of clinical trials; 5. The patient or guardian has signed the informed consent; 6. Patients completed written informed consent, International Physical Activity Scale, and dietary structure questionnaire, and committed to cooperate with the study throughout the trial period.
Exclusion criteria
Exclusion criteria: 1. Ethanol intake >40 g/ week. 2. Regular intake of nonsteroidal anti-inflammatory drugs, antibiotics and corticosteroids, antitumor drugs, antituberculous drugs, and some herbal and mineral drugs (alba/arsenic trinitride) in the past 6 months. 3. Abuse of drugs, psychotropic substances and cigarettes within the past six months. 4. Ingestion within the past 6 months of gastric acid deficiency, amiodarone, sodium valproate, prednisone, tamoxifen, piacoxicillin, and methotrexate, liver fat inducers, hormonal agents, statins, antihypertensives, and ursodeoxycholic acid antisecretory agents. 5. Take nutrient supplements such as probiotics, multivitamins/minerals, antioxidants, and ?-3 at least twice a week during the study or in the past 3 months. 6. Diseases affecting liver pathologic conditions, cholestasis, liver transplantation, acute systemic diseases, cystic fibrosis diseases, muscular dystrophy, neurological disorders, gastrointestinal structural abnormalities, diabetes mellitus, heart failure, thyroid disease, inflammatory bowel disease, kidney disease, respiratory failure, hereditary haemochromia, Wilson's disease, alpha-1 antitryptic deficiency, autoimmune diseases, celiac disease and any type of malignancy. 7. Rapid weight loss and total parenteral and protein malnutrition in the past 6 months. 8. Pregnant or lactating patients. 9. Allergies or intolerances to ingredients in the tested probiotic products. 10. Poor patient compliance and poor possibility of follow-up.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Height;Weight;Fecal flora;Fecal flora genomics;Blood routine;Hepatic function;Blood fat;Blood sugar;Fecal routine;All blood cells analysis;Serum IgE; | — |
Countries
China
Contacts
Public ContactGuo Jianfeng
Yixing People's Hospital
Outcome results
None listed